• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Entero Therapeutics' Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program

    7/31/24 7:00:00 AM ET
    $ENTO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ENTO alert in real time by email

    BOCA RATON, Fla., July 31, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ:ENTO), ("Entero Therapeutics" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today released a letter from James Sapirstein, the Company's Chairman and CEO, to provide stockholders with a business update.

    LETTER FROM OUR CHAIRMAN AND CHIEF EXECUTIVE OFFICER

    To my fellow stockholders,

    We are making substantial progress in the development and on the regulatory pathways with our lead product candidate, latiglutenase, a late-stage clinical asset for the treatment of celiac disease. Our primary focus is on advancing latiglutenase into a pivotal Phase 3 trial in 2025. Our recent regulatory agency interactions and operational changes outlined below reflect our sharp focus on positioning Entero for success with this lead program that can potentially address the unmet treatment needs for the millions of people currently struggling with celiac disease.

    After reviewing previous results from the Phase 2b clinical trial of latiglutenase, we decided to submit two Type D meeting requests to the FDA to build a more precise and efficient Phase 3 clinical trial design and development plan for latiglutenase.

    The first meeting request seeks approval to change the number of proposed cohorts in the latiglutenase Phase 3 trial from three (600 mg, 1200 mg and placebo) to two (1200 mg and placebo). Since the safety of 1200 mg of latiglutenase has been shown to be comparable to lower doses in previous Phase 2 trials, we believe the higher dose will maximize the efficacy of latiglutenase and provide us with the greatest potential to achieve success in the primary endpoint and key secondary endpoints. This adjustment should reduce the number of patients required for a Phase 3 trial and has the potential to both lower its estimated cost and shorten the time to an interim data read-out and trial completion by several months.

    We also plan to submit a second Type D meeting request in the next few weeks to finalize our histology-related secondary efficacy endpoints based on previous FDA communications and recent Phase 2 study results demonstrating statistically significant histologic improvements relative to placebo using the highest doses of latiglutenase.

    Additionally, we are preparing a response to the most recent end of Phase 2 and Type C meeting correspondence with the FDA to propose an updated protocol and streamlined trial design with the single-dose regimen and a focus on the most severe and symptomatic patient population demonstrating intestinal damage. These modifications are designed to expedite and maximize the potential success of the Phase 3 clinical trial.

    Despite the challenging market conditions affecting all clinical-stage biopharma companies, we completed a small financing that generated $1.9 million in gross proceeds to help support our movement toward initiation of the Phase 3 trial. We have also consolidated our bi-coastal operations into one office at our Boca Raton headquarters. This move streamlines processes, reduces overhead costs and creates a more cohesive work environment, enabling our team to work more efficiently and effectively toward our goals.

    We thank our stockholders for their continued support and confidence. By focusing our resources and efforts on our most promising program, we are in the strongest position for near-term success, which will serve as a foundation for the advancement of latiglutenase.

    Sincerely,

    James Sapirstein

    Chairman and CEO

    Entero Therapeutics, Inc.

    About Entero Therapeutics, Inc.

    Entero Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company is currently advancing a therapeutic development pipeline with multiple late-stage clinical programs built around three proprietary technologies: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist being developed for gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. Entero Therapeutics is headquartered in Boca Raton, Florida. For more information visit www.enterothera.com.

    Forward-Looking Statements

    This press release may contain certain statements relating to future results which are forward-looking statements. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including the Company's current and future capital requirements and its ability to raise additional funds to satisfy its capital needs, whether any financing or licensing transaction may be obtained, completed in an untimely manner, or not at all; whether the Company will be able to realize the expected benefits of its acquisition of ImmunogenX; the Company's ability to integrate the assets and contemplated commercial operations acquired from ImmunogenX into the Company's business; whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial will be indicative of the final results of the trial; whether the Company will be able to maintain compliance with Nasdaq's continued listing criteria and the effect of a delisting from Nasdaq on the market for the Company's securities; the size of the potential markets for the Company's drug candidates and its ability to service those markets; and the effects of the First Wave Bio, Inc. acquisition, the related settlement and their effect on the Company's business, operating results and financial prospects. Additional information concerning the Company and its business, including a discussion of factors that could materially affect the Company's financial results are contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, under the heading "Risk Factors," as well as the Company's subsequent filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

    For more information:

    Entero Therapeutics, Inc.

    777 Yamato Road, Suite 502

    Boca Raton, FL 33431

    Phone: (561) 589-7020

    [email protected]

    Media contact:

    Russo Partners

    David Schull or Liz Phillips

    (347) 956-7697

    [email protected]

    [email protected]



    Primary Logo

    Get the next $ENTO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ENTO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ENTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Uppal Manpreet

      3 - Entero Therapeutics, Inc. (0001604191) (Issuer)

      2/13/25 5:02:13 PM ET
      $ENTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Corbett Eric

      3 - Entero Therapeutics, Inc. (0001604191) (Issuer)

      2/13/25 5:00:59 PM ET
      $ENTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Paolone Richard

      3 - Entero Therapeutics, Inc. (0001604191) (Issuer)

      2/13/25 4:59:40 PM ET
      $ENTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Entero Therapeutics Appoints Richard Paolone as CEO

      BOCA RATON, Fla., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (NASDAQ:ENTO) ("Entero" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that the board of directors has appointed Mr. Richard Paolone as the interim CEO of the Company. Richard Paolone is a Toronto-based securities lawyer with extensive experience in corporate finance, securities law, and mergers and acquisitions. Mr. Paolone plays a key role in advising on a range of strategic business initiatives and has represented numerous companies in both private and public offerings of debt

      2/14/25 4:00:00 PM ET
      $ENTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members

      BOCA RATON, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (NASDAQ:ENTO) ("Entero" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that it has secured a $2 million revolving loan agreement and subsequently appointed three new members to its Board of Directors. As a condition for the loan, Entero replaced three of five members of its Board of Directors with three new directors designated by the lender. These appointments follow the resignations of James Sapirstein, Alastair Riddell and Timothy Ramdeen from the Board. Richard Paolone, a Tor

      2/7/25 3:22:22 PM ET
      $ENTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum

      BOCA RATON, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ:ENTO), ("Entero Therapeutics" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and CEO of Entero Therapeutics, will moderate the "CEO Insights: Lessons Learned & Strategies for Driving Innovation," CEO Forum which will be held on Tuesday, November 19, 2024 at the Swan Hotel in Orlando, Florida. The session will feature several CEOs as panelists and will be open to senior executives from the Florida Life Science ecosystem. Details of the even

      11/14/24 8:00:00 AM ET
      $ENTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTO
    Leadership Updates

    Live Leadership Updates

    See more
    • Entero Therapeutics Appoints Richard Paolone as CEO

      BOCA RATON, Fla., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (NASDAQ:ENTO) ("Entero" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that the board of directors has appointed Mr. Richard Paolone as the interim CEO of the Company. Richard Paolone is a Toronto-based securities lawyer with extensive experience in corporate finance, securities law, and mergers and acquisitions. Mr. Paolone plays a key role in advising on a range of strategic business initiatives and has represented numerous companies in both private and public offerings of debt

      2/14/25 4:00:00 PM ET
      $ENTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

      Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

      10/8/24 5:00:00 AM ET
      $ENTO
      $OCS
      $ONCO
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTO
    SEC Filings

    See more
    • SEC Form PRER14A filed by Entero Therapeutics Inc.

      PRER14A - Entero Therapeutics, Inc. (0001604191) (Filer)

      5/30/25 5:25:48 PM ET
      $ENTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRER14A filed by Entero Therapeutics Inc.

      PRER14A - Entero Therapeutics, Inc. (0001604191) (Filer)

      5/27/25 6:09:04 AM ET
      $ENTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Entero Therapeutics Inc.

      PRE 14A - Entero Therapeutics, Inc. (0001604191) (Filer)

      5/16/25 5:04:32 PM ET
      $ENTO
      Biotechnology: Pharmaceutical Preparations
      Health Care